Subscribe To

Price Alert Latest News Economic Calendar News

RNLX / Renalytix surges 28% Medicaid news

Shares of Renalytix PLC (AIM:RENX) surged 28% in early trading after the Centers for Medicare & Medicaid Services (CMS) announced a price of $950 for the company's FDA-approved kidneyintelX.dkd test. The test, which uses artificial intelligence to predict risks for people with type 2 diabetes and chronic kidney disease, will be listed on the nationwide Clinical Laboratory Fee Schedule starting January 1, and the price will be locked in for at least three years. Read More

Demo Live Account See Partner Details

Content Topics

Renalytix

Surges

Medicaid

News

Stock

RNLX

Posted: Oct 3 2023, 04:09

Author Name: Proactive Investors

RNLX News

By Zacks Investment Research
October 16, 2023

What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock

Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings pros

By Proactive Investors
October 6, 2023

Renalytix sinks to near year low despite news of strengthening US patents

Renalytix PLC (AIM:RENX) shares fell 12% to 46.09p after it said newly allowed US patents further strengthen the core intellectual property underpi

By Zacks Investment Research
October 5, 2023

Renalytix AI PLC Sponsored ADR (RNLX) Loses -44.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Renalytix AI PLC Sponsored ADR (RNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with st

By Proactive Investors
October 3, 2023

Renalytix surges 28% Medicaid news

Shares of Renalytix PLC (AIM:RENX) surged 28% in early trading after the Centers for Medicare & Medicaid Services (CMS) announced a price of $950 for

By Seeking Alpha
September 29, 2023

Renalytix Plc (RNLX) Q4 2023 Earnings Call Transcript

Renalytix Plc (NASDAQ:RNLX ) Q4 2023 Earnings Conference Call September 28, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners Jame

By Proactive Investors
July 21, 2023

Renalytix jumps on Middle East distribution deal, 'region with most diabetes globally'

Renalytix PLC (AIM:RENX) shares ramped 7.5% higher to 128.95p on Friday morning after it announced a distribution agreement for its kidneyintelX.dkd

By Seeking Alpha
July 16, 2023

Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool

Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval and established insurance reimbursement, p

By InvestorPlace
June 30, 2023

Why Is Renalytix (RNLX) Stock Up 45% Today?

Renalytix (NASDAQ: RNLX ) stock is rising higher on Friday after the medical company got marketing permission from the FDA. According to a press relea

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.